News

  • HOME
  • News
  • 【Research Highlight】 SPERA PHARMA at OMCOS XXⅡ – Exhibition & Poster Presentation

【Research Highlight】 SPERA PHARMA at OMCOS XXⅡ – Exhibition & Poster Presentation

2025.08.07

We are pleased to announce that researchers from SPERA PHARMA (Chemical R&D Laboratory) —Keiyo Nakai, Takahiro Konishi, Mitsuhisa Ymano, and Kuniyoshi Miki—will present their research findings in a poster session at the 22nd International Symposium on Organometallic Chemistry Directed Towards Organic Synthesis (OMCOS XXⅡ), to be held at Hotel Granvia Kyoto on September 1–5, 2025.

 

OMCOS XXⅡ

   DATE:  September 1-5, 2025
   VENUE: Hotel Granvia Kyoto, Japan
   Booth No.: 3

 

★Poster presentation

   Poster Title: 【PB-080】3D ED/MicroED structural analysis of various organometallic complexes

   Authors: 〇Keiyo Nakaia, Takahiro Konishia, Takashi Kikuchib, Kuniyoshi Mikia,
              Mitsuhisa Yamanoa
          (a SPERA Pharma, Inc., b Rigaku Corporation)

 

SPERA PHARMA has recently introduced a state-of-the-art 3D ED/MicroED crystallographic structure analysis system (Synergy-ED, manufactured by Rigaku Corporation and JEOL Ltd.), enhancing our capabilities in resolving complex crystallographic challenges through advanced structural analysis.
In parallel, we have inherited extensive expertise from our time at Takeda Pharmaceutical and continue to advance asymmetric reduction reactions using a variety of chiral ligands. Notably, our screening capabilities for ruthenium-catalyzed asymmetric reductions are recognized as among the best in the world.
We conducted a feasibility study to evaluate the structural determination power of 3D ED/MicroED in analyzing organometallic complexes. The study confirmed that this technology enables rapid determination of absolute stereochemistry—an area that traditionally required considerable time—significantly streamlining the structural analysis process. We sincerely hope that these steady efforts in structure determination will contribute to the development of various reactions using organometallic catalysts.

 

At SPERA PHARMA, we apply this analytical technology not only to organometallic complexes but also to the elucidation of crystal polymorphs, APIs in formulations, salts/co-crystals, and metabolites. Through providing accurate and timely structural insights, we remain committed to empowering our clients in overcoming their development challenges.

 

We sincerely look forward to welcoming you to our exhibition booth and poster presentation.
For inquiries regarding this service, please click the button below.

Inquiry

page top